Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec Licenses CRISPR-Cas9 Gene Editing Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Evotec Licenses CRISPR-Cas9 Gene Editing Technology

Will apply CRISPR-Cas9 technology to its drug discovery offerings and R&D activities

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec AG has entered into a non-exclusive license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, as well as for the development of research tools in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.

Dr. Mario Polywka, chief operating officer of Evotec, said, “Alongside Evotec’s comprehensive stem cell capabilities, the ability to offer CRISPR-Cas9 research tools emphasises the Company’s continuing approach to establishing cutting-edge technologies for the benefit of our partners and growing R&D pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics